Reuters logo
BRIEF-Preliminary 19.2 vs 14.4 months OS benefit in Roche lung cancer trial
December 7, 2017 / 11:52 AM / 11 days ago

BRIEF-Preliminary 19.2 vs 14.4 months OS benefit in Roche lung cancer trial

Dec 7 (Reuters) - Principal investigator on Roche Impower 150 clinical trial tells press conference in Geneva:

* IMPOWER 150 LUNG CANCER STUDY SHOWS PRELIMINARY OVERALL SURVIVAL BENEFIT OF 19.2 MONTHS VERSUS 14.4 MONTHS, HAZARD RATIO 0.775; DATA NOT YET MATURE Further company coverage: (Reporting by UK bureau)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below